205 related articles for article (PubMed ID: 31152919)
1. Primary peg-filgrastim prophylaxis versus filgrastim given "on demand" for neutropenia during therapy with cladribine for hairy cell leukemia.
Tadmor T; Levy I; Herishanu Y; Goldschmidt N; Bairey O; Yuklea M; Shvidel L; Fineman R; Aviv A; Ruchlemer R; Braester A; Dally N; Rouvio O; Shaulov A; Greenbaum U; Inbar M; Polliack A
Leuk Res; 2019 Jul; 82():24-28. PubMed ID: 31152919
[TBL] [Abstract][Full Text] [Related]
2. Filgrastim for cladribine-induced neutropenic fever in patients with hairy cell leukemia.
Saven A; Burian C; Adusumalli J; Koziol JA
Blood; 1999 Apr; 93(8):2471-7. PubMed ID: 10194424
[TBL] [Abstract][Full Text] [Related]
3. Pegfilgrastim prophylaxis for cladribine-induced neutropenia in patients with hairy-cell leukemia.
Goldschmidt N; Ganzel C; Attias D; Gatt M; Polliack A; Tadmor T
Acta Haematol; 2014; 132(1):118-21. PubMed ID: 24557414
[No Abstract] [Full Text] [Related]
4. Factors Associated with Absolute Neutrophil Count Dynamics and Docetaxel-Adryamicin-Cyclophosphamide (TAC) Chemotherapy Induced Neutropenia During Extended Filgrastim Administration in Breast Cancer Patients.
Ashariati A; Bintoro UY; Savitri M; Diansyah MN; Amrita PNA; Romadhon PZ; Wijaya AY; Hendrata WM; Looi SS; Mahmudin AA
Acta Med Indones; 2022 Jul; 54(3):371-378. PubMed ID: 36156473
[TBL] [Abstract][Full Text] [Related]
5. Inhibitor of BRAF
Smirnova SY; Al-Radi LS; Moiseeva TN; Gemdzhian EG; Yakutik IA; Julhakyan HL; Novikov VA; Galstyan GM; Sudarikov AB
Clin Lymphoma Myeloma Leuk; 2021 Jul; 21(7):427-430. PubMed ID: 33811006
[TBL] [Abstract][Full Text] [Related]
6. Neutropenic fever following cladribine therapy for symptomatic hairy-cell leukemia: predictive factors and effects of granulocyte-macrophage colony-stimulating factor.
Juliusson G; Lenkei R; Tjønnfjord G; Heldal D; Liliemark J
Ann Oncol; 1995 Apr; 6(4):371-5. PubMed ID: 7619752
[TBL] [Abstract][Full Text] [Related]
7. A Comparison of Brand and Biosimilar Granulocyte-Colony Stimulating Factors for Prophylaxis of Chemotherapy-Induced Febrile Neutropenia.
Douglas AG; Schwab P; Lane D; Kennedy K; Slabaugh SL; Bowe A
J Manag Care Spec Pharm; 2017 Dec; 23(12):1221-1226. PubMed ID: 29172983
[TBL] [Abstract][Full Text] [Related]
8. 2-chlorodeoxyadenosine (cladribine) in the treatment of hairy cell leukemia and hairy cell leukemia variant: 7-year experience in Poland.
Robak T; Błasińska-Morawiec M; Błoński J; Hellmann A; Hałaburda K; Konopka L; Kotlarek-Haus S; Potoczek S; Hansz J; Dmoszyńska A; Urasiński I; Zdziarska B; Dwilewicz-Trojaczek J; Hołowiecki J; Skotnicki AB
Eur J Haematol; 1999 Jan; 62(1):49-56. PubMed ID: 9918312
[TBL] [Abstract][Full Text] [Related]
9. Remission of early persistent cladribine-induced neutropenia after filgrastim therapy in a patient with Relapsing - Remitting Multiple Sclerosis.
Maniscalco GT; Annunziata M; Ranieri A; Alfieri G; Renna R; Iorio WD; Guarcello G; Cerillo I; Improta G; Florio C
Mult Scler Relat Disord; 2020 Aug; 43():102151. PubMed ID: 32417665
[TBL] [Abstract][Full Text] [Related]
10. Risk of hospitalization for neutropenic complications of chemotherapy in patients with primary solid tumors receiving pegfilgrastim or filgrastim prophylaxis: a retrospective cohort study.
Weycker D; Malin J; Kim J; Barron R; Edelsberg J; Kartashov A; Oster G
Clin Ther; 2009 May; 31(5):1069-81. PubMed ID: 19539108
[TBL] [Abstract][Full Text] [Related]
11. Filgrastim in patients with chemotherapy-induced febrile neutropenia. A double-blind, placebo-controlled trial.
Maher DW; Lieschke GJ; Green M; Bishop J; Stuart-Harris R; Wolf M; Sheridan WP; Kefford RF; Cebon J; Olver I; McKendrick J; Toner G; Bradstock K; Lieschke M; Cruickshank S; Tomita DK; Hoffman EW; Fox RM; Morstyn G
Ann Intern Med; 1994 Oct; 121(7):492-501. PubMed ID: 7520676
[TBL] [Abstract][Full Text] [Related]
12. High incidence of skin rash in patients with hairy cell leukemia treated with cladribine.
Ganzel C; Gatt ME; Maly A; Ben-Yehuda D; Goldschmidt N
Leuk Lymphoma; 2012 Jun; 53(6):1169-73. PubMed ID: 22035415
[TBL] [Abstract][Full Text] [Related]
13. Treatment of hairy cell leukemia with cladribine (2-chlorodeoxyadenosine) by subcutaneous bolus injection: a phase II study.
von Rohr A; Schmitz SF; Tichelli A; Hess U; Piguet D; Wernli M; Frickhofen N; Konwalinka G; Zulian G; Ghielmini M; Rufener B; Racine C; Fey MF; Cerny T; Betticher D; Tobler A;
Ann Oncol; 2002 Oct; 13(10):1641-9. PubMed ID: 12377655
[TBL] [Abstract][Full Text] [Related]
14. Real-world data on diagnostics, treatment and outcomes of patients with hairy cell leukemia: The HCL-CLLEAR study.
Panovská A; Žák P; Jurková T; Arpáš T; Brychtová Y; Vašíková A; Hrabčáková V; Prchlíková A; Filipová M; Doubek M
Hematol Oncol; 2024 May; 42(3):e3280. PubMed ID: 38741354
[TBL] [Abstract][Full Text] [Related]
15. Retrospective comparison of neutropenia in children with Ewing sarcoma treated with chemotherapy and granulocyte colony-stimulating factor (G-CSF) or pegylated G-CSF.
Milano-Bausset E; Gaudart J; Rome A; Coze C; Gentet JC; Padovani L; Lacarelle B; André N
Clin Ther; 2009; 31 Pt 2():2388-95. PubMed ID: 20110048
[TBL] [Abstract][Full Text] [Related]
16. Treatment patterns and outcomes in the prophylaxis of chemotherapy-induced (febrile) neutropenia with biosimilar filgrastim (the MONITOR-GCSF study).
Gascón P; Aapro M; Ludwig H; Bokemeyer C; Boccadoro M; Turner M; Denhaerynck K; MacDonald K; Abraham I
Support Care Cancer; 2016 Feb; 24(2):911-925. PubMed ID: 26306517
[TBL] [Abstract][Full Text] [Related]
17. Safety and Efficacy of Pegfilgrastim When Given Less Than 14 Days Before the Next Chemotherapy Cycle: Review of Every 14-Day Chemotherapy Regimen Containing 5-FU Continuous Infusion.
Donkor KN; Selim JH; Waworuntu A; Lewis K
Ann Pharmacother; 2017 Oct; 51(10):840-847. PubMed ID: 28597691
[TBL] [Abstract][Full Text] [Related]
18. A randomized, multi-center, open-label, phase III study of once-per-cycle DA-3031, a pegylated G-CSF, in comparison with daily filgrastim in patients receiving TAC chemotherapy for breast cancer.
Park KH; Lee S; Park JH; Kang SY; Kim HY; Park IH; Park YH; Im YH; Lee HJ; Park S; Lee SI; Jung KH; Kim YS; Seo JH
Support Care Cancer; 2017 Feb; 25(2):505-511. PubMed ID: 27709313
[TBL] [Abstract][Full Text] [Related]
19. Prophylaxis of chemotherapy-induced neutropenia and febrile neutropenia with lipegfilgrastim in patients with non-Hodgkin lymphoma (NADIR study).
Wolff T; Schulz H; Losem C; Reichert D; Hurtz HJ; Sandner R; Harde J; Grebhardt S; Potthoff K; Mueller U; Fietz T
Eur J Haematol; 2019 Feb; 102(2):174-181. PubMed ID: 30347466
[TBL] [Abstract][Full Text] [Related]
20. Hairy Cell Leukemia: Retrospective Analysis of Demographic Data and Outcome of 203 Patients from 12 Medical Centers in Israel.
Inbar M; Herishanu Y; Goldschmidt N; Bairey O; Yuklea M; Shvidel L; Fineman R; Aviv A; Ruchlemer R; Braester A; Najib D; Rouvio O; Shaulov A; Greenbaum U; Polliack A; Tadmor T
Anticancer Res; 2018 Nov; 38(11):6423-6429. PubMed ID: 30396967
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
